文献速递主动脉疾病

感染性自体腹主动脉瘤腔内与开放修复的10年回顾性比较

A 10-Year Retrospective Comparison of Endovascular and Open Aneurysm Repair for Infective Native Abdominal Aortic Aneurysm.
PubMed 文献 · Ann Vasc Surg · 2024-11-22

回顾性比较2004年1月至2019年12月125例感染性自体腹主动脉瘤患者(EVAR 80例,OAR 45例)的10年结局。EVAR组不适合手术者比例更高(51.2% vs 22.2%,P=0.003)。30天死亡率、住院死亡率、抗生素疗程、10年总生存率和无再干预时间两组均无显著差异;不适合手术状态是30天死亡的独立预测因素(校正OR 10.654,95%CI 1.041-109.030,P=0.046)。

要点

  • EVAR组不适合手术者比例高于OAR组(51.2% vs 22.2%,P=0.003)。
  • 30天死亡率EVAR组7.5% vs OAR组4.4%,OR 1.75(95%CI 0.34-9.06),P=0.508。
  • 不适合手术状态是30天死亡的独立预测因素(校正OR 10.654,95%CI 1.041-109.030,P=0.046)。

核心结论

  • EVAR与OAR在感染性自体腹主动脉瘤管理中提供可比结局,尽管EVAR更多用于不适合手术患者。
  • 两种方法早期死亡率、抗生素疗程和长期生存相似,支持EVAR作为OAR的可行替代方案。
  • 不适合手术状态独立预测围手术期死亡率,强调患者选择在治疗决策中的关键作用。
  • 作者认为EVAR可能特别有利于不适合OAR的高危感染性自体腹主动脉瘤患者。

研究设计与样本

  • 回顾性队列研究,纳入2004年1月至2019年12月诊断的125例感染性自体腹主动脉瘤患者(EVAR 80例,OAR 45例)。
  • 依据EVAR-1和EVAR-2试验建立的指南,按心脏、呼吸和肾脏状态将患者分为适合或不适合开放手术。
  • 主要结局为30天和住院死亡率;次要结局包括需再干预的早期和晚期并发症、抗生素疗程、10年总生存率、10年无再干预生存率及影响30天死亡率的因素。

主要发现

  • 男性在OAR组为37/45(82.2%),在EVAR组为62/80(77.5%),P=0.693。
  • 平均年龄OAR组64.8±9.8岁 vs EVAR组69.0±12.6岁,P=0.063。
  • 腹主动脉是最常见动脉瘤位置,91/125(72.8%);沙门菌属占阳性培养病例19/45(42.2%);34/125(27.2%)患者动脉瘤破裂。
  • 30天死亡率EVAR组6/80(7.5%) vs OAR组2/45(4.4%),OR=1.75(95%CI 0.34-9.06),P=0.508;住院死亡率EVAR组7/80(8.8%) vs OAR组5/45(11.1%),OR=0.77(95%CI 0.23-2.58),P=0.668。
  • 抗生素疗程中位数11 vs 6个月(P=0.594)、10年总生存率62.8% vs 64.8%(P=0.90)、无再干预时间83.8% vs 82.2%(P=0.922)、动脉瘤相关死亡84.7% vs 92.9%(P=0.159)均无显著差异。

关键数值与推荐

  • 30天死亡率EVAR组6/80(7.5%) vs OAR组2/45(4.4%),OR=1.75(95%CI 0.34-9.06),P=0.508。
  • 住院死亡率EVAR组7/80(8.8%) vs OAR组5/45(11.1%),OR=0.77(95%CI 0.23-2.58),P=0.668。
  • 不适合手术状态预测30天死亡的校正OR=10.654(95%CI 1.041-109.030),P=0.046。

临床怎么用

  • 作者认为EVAR与OAR结局可比,支持EVAR作为OAR的可行替代方案。
  • 作者认为EVAR可能特别有利于不适合OAR的高危感染性自体腹主动脉瘤患者。
  • 作者强调患者选择在治疗决策中的关键作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study compared outcomes of endovascular (EVAR) and open aneurysm repair (OAR) in patients with infective native abdominal aortic aneurysms (INAAAs), evaluating perioperative and in-hospital mortality, antibiotic treatment duration, complications, overall survival rates, and reintervention-free times at 10 years. METHODS: A retrospective cohort study of 125 INAAA patients (80 EVAR, 45 OAR) diagnosed between January 2004 and December 2019 was conducted. Patients were categorized as fit or unfit for open surgery based on cardiac, respiratory, and renal status, following the guidelines established in the EVAR-1 and EVAR-2 trials. Primary outcomes included 30-day and in-hospital mortality. Secondary outcomes encompassed early and late complications requiring reintervention, antibiotic treatment duration, 10-year overall survival, 10-year reintervention-free survival, and factors influencing 30-day mortality. Statistical analysis used chi-square, t-tests, and Mann-Whitney U tests. Logistic regression assessed mortality. Kaplan-Meier estimation evaluated survival. Analyses used SPSS version 18.0 (P < 0.05 considered significant) RESULTS: Males predominated in both OAR (37 of 45, 82.2%) and EVAR (62 of 80, 77.5%) groups (P = 0.693). Mean age was 64.8 ± 9.8 years for OAR and 69.0 ± 12.6 years for EVAR (P = 0.063). The abdominal aorta was the most common aneurysm location, accounting for 91 of 125 (72.8%) cases. Salmonella spp. accounted for 19 of 45 (42.2%) of positive culture cases, and 34 of 125 (27.2%) patients had ruptured aneurysms. The EVAR group had a higher proportion of unfit patients (41 of 80, 51.2%) compared to OAR (10 of 45,22.2%; P = 0.003). Thirty-day mortality rates were 6 of 80 (7.5%) for EVAR and 2 of 45 (4.4%) for OAR; odds ratio (OR) = 1.75 (95% confidence interval (CI): 0.34-9.06), P = 0.508, while in-hospital mortality rates were 7 of 80 (8.8%) and 5 of 45 (11.1%); OR = 0.77 (95% CI: 0.23-2.58), P = 0.668. No significant differences were found in antibiotic treatment duration (median 11 vs. 6 months, P = 0.594), 10-year overall survival rates (62.8% vs. 64.8%, P = 0.90), or reintervention-free time (83.8% vs. 82.2%, P = 0.922), and aneurysm-related death (84.7% vs. 92.9%, P = 0.159). Unfit patient status was an independent predictor of 30-day mortality (adjusted OR, 10.654; 95% CI, 1.041-109.030; P = 0.046). CONCLUSIONS: Our study demonstrates that EVAR and OAR provide comparable outcomes in INAAA management, despite EVAR being performed more frequently in unfit patients. The similar early mortality rates, antibiotic treatment durations, and long-term survival between the 2 approaches support EVAR as a viable alternative to OAR. Importantly, our finding that unfit patient status independently predicts perioperative mortality emphasizes the critical role of patient selection in treatment decisions. These results collectively suggest that EVAR may be particularly beneficial for high-risk INAAA patients unsuitable for OAR, potentially expanding treatment options for this challenging condition.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chinsakchai K, Khunprasert P, Ruangsetakit C, et al. A 10-Year Retrospective Comparison of Endovascular and Open Aneurysm Repair for Infective Native Abdominal Aortic Aneurysm. Ann Vasc Surg. 2024. PMID: 39581315. doi:10.1016/j.avsg.2024.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。